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1010 The Journal of Thoracic and CardObjective: Novel antigen-reduction SynerGraft technology (CryoLife Inc, Kenne-
saw, Ga) reduces the cellular components of a cadaver homograft with an enzymatic
and washing process, leaving the extracellular matrix intact. We report the immu-
noreactivity (positive panel reactive antibody assay) and early operative results of
the CryoLife SynerGraft aortic valve conduit homograft.
Methods: Twenty-two patients (age 53  14 years, range 31-80 years) from April
2002 to July 2003 underwent aortic root replacement with a CryoLife SynerGraft
aortic valve conduit homograft (CryoLife Inc, Kennesaw, Ga) for congenital or
acquired aortic valve disease, aortic aneurysm with aortic valve disease, or native or
prosthetic aortic valve endocarditis. Baseline percentage positive panel reactive
antibody results were negative (10%) for all and were assessed at 1 month, 3
months, and 1-year. Homograft function was evaluated by echocardiography.
Results: Early mortality was 0%. Two late deaths at 1 postoperative year were
unrelated to homograft function. At 1 postoperative month, panel reactive antibody
results were negative in 20 patients (91%). At 3 months, 19 of 22 patients (86%) had
negative results, including 1 with previous positive results. At 1 year, 19 of 20
patients (95%) had negative results, including 2 of the 3 with previous positive
results. The mean aortic valve gradients were 12  8 mm Hg (n  21) at discharge
and 11  7 mm Hg (n  18) at 1 year. At a mean follow-up of 30.3  5.2 months,
the mean gradient was 8.8  6.3 mm Hg.
Conclusion: The SynerGraft decellularization technology successfully removed
antigens from an aortic valve homograft conduit. Aortic root reconstruction with the
CryoLife SynerGraft aortic valve homograft resulted in low transvalvular gradients,
similar to those seen with standard cryopreserved homografts. These early results
suggest an advancement in homograft technology. The low panel reactive antibody
response may enhance durability by eliminating immune complex–mediated reac-
tion against the homograft. The lack of allosensitization in patients who may require
organ transplantation in the future is an added benefit.
Aortic and pulmonary valve conduit homografts are associated with lowtransvalvular gradients and nearly normal exercise hemodynamics.1-5 Thisfavorable hemodynamic profile, the lack of need for anticoagulation, and
the low incidence of endocarditis, make these tissue reconstructions appealing for
young, active adults, patients with contraindications to anticoagulation, and patients
with endocarditis. In the aortic position, homografts have a significant structural
deterioration curve beginning at 10 years, with few implants lasting as long 20 years
postimplantation.6,7 In the pulmonary position, graft stenosis can prevent long-term
durability.8 A persistent immunoreactivity against donor antigens has been impli-
cated.9,10 Early calcification and stenosis from an intense inflammatory reaction may
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failure has been shown to be more prevalent in younger
patients, perhaps because of a more aggressive immune
response.6
In an attempt to reduce the antigenic response, decellu-
larization processes have been introduced for cryopreserved
tissue.11 Experimental and clinical experience with this
decellularization process has been gained with porcine vena
cava porcine tissue,12 porcine aortic13 and pulmonary valve
Figure 1. Photomicrograph of aortic wall of decellularized cryo-
preserved aortic homograft. Note nearly complete accellularity of
tissue with maintenance of extracellular matrix (original magni-
fication 20, hematoxylin and eosin).
Figure 2. Photomicrograph of aortic wall of standard cryopre-
served aortic homograft. Note presence of cellularity of tissue
(original magnification 20, hematoxylin and eosin).
The Journal of Thoracicconduits, ovine pulmonary valve conduits,14 and, subse-
quently, human femoral vein15 and human pulmonary valve
conduits.11,16 All have proved to be minimally immunore-
active. There has also been experimental evidence that the
decellularized matrix becomes populated with functional
recipient cells.11,14
Until this study, it has not been definitively shown
whether application of this decellularization process to
thicker, bulkier, more robust human aortic valve conduits
would result in the absence of a persistent humoral re-
sponse. We sought to assess the immunoreactivity and early
hemodynamic results of decellularized cryopreserved aortic
valve conduits after aortic root reconstruction. Persistent lack
of immunoreactivity theoretically could result in increased
durability and increased chance of recipient recellularization.
An added benefit would be the lack of allosensitization in




Aortic valve conduits were treated with a proprietary decellular-
ization process (SynerGraft technology, CryoLife, Inc, Kennesaw,
Ga). The steps include cell lysis in hypotonic solution, enzymatic
digestion of nucleic acids, and washout in isotonic, neutral buffer.
The valves were then cryopreserved with dimethyl sulfoxide and
stored in liquid nitrogen until implantation.
Patients and Surgical Procedure
Twenty-two patients (age 53  14 years, 18 male, 4 female, age
range 31-80 years) from April 2002 through July 2003 underwent
aortic root replacement with a CryoLife SynerGraft aortic valve
conduit homograft. Eight patients had congenital unicuspid or
bicuspid aortic valve disease, 6 had acquired tricuspid aortic valve
stenosis, 6 had an ascending aortic aneurysm with aortic valve
Figure 3. Decellularized cryopreserved aortic homograft during
aortic root replacement.disease, and 1 each had native and prosthetic aortic valve endo-
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ments with reimplantation of the coronary ostia as buttons. Micro-
scopic analysis of representative SynerGraft aortic tissue samples
revealed nearly complete conduit accellularity (Figure 1) com-
pared to standard cryopreserved aortic homografts (Figure 2). The
gross appearance of the homografts appeared similar to standard
cryopreserved homografts (Figure 3). The Mayo Clinic Internal
Review Board approved and monitored this prospective protocol.
Panel Reactive Antibody Testing
Patient allosensitization was quantified by panel reactive antibody
(PRA) assay. Peripheral blood samples were obtained before the
operation and at 1 month, 3 months, and 1 year after the operation.
Testing was performed by the Mayo Clinic Laboratories in accor-
dance with the American Society for Histocompatibility and Im-
munogenetics laboratory protocol.17 An antiglobulin-mediated
complement-dependent cytotoxicity assay on a frozen 50-cell
panel was used to determine the presence and spectrum of anti-
body. A positive cell result was defined as an assay which resulted
in greater than 50% cytotoxicity relative to negative control serum
samples. The percentage positive PRA reported is the percentage
of reactive cells on the panel. A PRA greater than 10% was
considered to be a positive antibody determination. Baseline PRA
were results were negative (10% PRA) for all patients.
Echocardiography
Transthoracic echocardiography was performed before the opera-
tion, at discharge, at 1 postoperative year and at latest follow-up.
Intraoperative transesophageal echocardiography was performed
in all cases.
Results
There were no in-hospital deaths. There were two late
deaths at 1 postoperative year. Both deaths were unrelated
to the homograft; 1 was of congestive heart failure second-
ary to severe cardiomyopathy related to long-standing aortic
regurgitation before the operation, and 1 was of sepsis
resulting from lower extremity diabetic gangrene. Unfortu-
nately, these valve conduits could not be obtained for patho-
logic analysis. The deaths occurred before the 1-year PRA
assay.
At 1 month after the operation, PRA results were nega-
tive in 20 of 22 patients (91%). Two patients (9%) had PRA
percentages of 48% and 79%. At 3 months, PRA results
were negative in 19 of 22 patients (86%), including 1 with
a previous positive result. Three patients had positive PRA
percentages (11%, 21%, and 61%). At 1 year, 19 of 20
(95%) patients had negative results, including 2 patients
with previous positive results. The remaining patient with a
positive result had a PRA percentage of 16%. There was no
statistical correlation between blood product transfusion and
positive PRA result. Twelve patients required postoperative
blood transfusions. The blood products were not leukocyte
depleted or irradiated. Only 2 of these patients had positive
PRA results.
1012 The Journal of Thoracic and Cardiovascular Surgery ● OctThe mean aortic valve gradients were 12  8 mm Hg
(n  21) at discharge and 11  7 mm Hg (n  18) at 1
postoperative year (difference not significant). At a mean
follow-up of 30.3  5.2 months, the mean gradient was 8.8
 6.3 mm Hg. The postoperative maximal aortic root di-
ameters were 33.25  3.8 mm on discharge echocardiog-
raphy and 32.6  3.2 mm at 1-year echocardiography
(difference not significant). No patients had more than triv-
ial aortic valve regurgitation. There were no adverse events
of thromboembolism or endocarditis. No patients received
anticoagulation during follow-up.
Discussion
The most significant finding of this study is that antigens
can be successfully removed from aortic valve conduit
homografts, resulting in essentially no presence of antibody
at 1 postoperative year. Although there were no side-by-side
control subjects, there is ample evidence in the literature
that traditionally prepared cryopreserved allograft tissue
incites a broad, strong, and persistent humoral response to
donor HLA antigens. Welters and colleagues18 found
greater than 10% positive PRA results in 31 of 35 heart
valve homograft recipients (89%). Among the patients with
positive results, 24 (77%) had donor-specific HLA class I
antibodies develop. Antibody titers were followed longitu-
dinally in 8 patients with greater than 50% PRA. Maximal
titers were found at 6 months, and 5 patients had elevated
titers at 1 year. Benedetto and associates19 studied 20 con-
secutive patients who received a cryopreserved vein ho-
mograft fistula for hemodialysis. Mean PRA assay values
were 84.1% (median 96.5%) at a mean of 3.1 postoperative
months. They concluded that these traditionally cryopre-
served allografts should not be used in potential kidney
transplant candidates because of the significant allosensiti-
zation incurred. Piatosa and colleagues20 found that 12 of 14
patients had positive PRA results as long as 3 months after
homograft heart valve implantation. IgG anti-HLA antibod-
ies in the serum were antidonor specific; 6 patients had
anticlass I antigens and 6 patients had class II antigens.
The clinical relevance of the immune response is not
clear. Evidence suggests that it does play a role in ho-
mograft failure. In our patients, echocardiography at 30
months’ mean follow-up showed no evidence of aortic wall
calcifications and also showed normal cusps. Further fol-
low-up is needed, however, because calcification rarely
occurs so quickly after implantation. Koolbergen and asso-
ciates21 studied 40 explanted homografts implanted from 14
days to 16 years. They found a persistent low-grade inflam-
matory response but did not find conclusive data supporting
graft failure caused by immune-mediated injury. A few
reports have documented a significant immune response
associated with homograft failure. Welters and colleagues18
reported on a patient with early allograft failure thought to
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specific anti-HLA antibody titers (1:8000). Carr-White and
coworkers8 reported on 4 patients who were reoperated on
for rapidly progressive pulmonary homograft stenosis after
a Ross procedure. Significant postoperative inflammatory
reaction was diagnosed both macroscopically and micro-
scopically. Indirect evidence implicating the immune re-
sponse in reducing allograft durability is provided by the
relatively more rapid deterioration of standard cryopre-
served tissue in children and young adults. It is also inter-
esting to observe that conduit calcification and valve dete-
rioration is rarely seen in immune-suppressed patients after
cardiac transplantation. Logically, it would follow that tis-
sue typing might increase durability of homograft tissue.
This has been difficult to prove. Bechtel and associates5
tissue typed pulmonary homografts implanted during the
Ross procedure in 26 patients for HLA-A, HLA-B, and
HLA-DR. Fifty-four percent of patients had anti-HLA class
I antibody positive results at a mean follow-up of 15  6
months. A significant transhomograft pressure gradient in-
crease was observed during this time, but there was no
demonstrable relationship with the degree of histocompati-
bility. In a larger series of 47 patients (57% positive PRA),
the same group4 observed no differences in transpulmonary
pressure gradient or degree of pulmonary regurgitation ac-
cording to the presence or absence of anti-HLA antibodies.
There has been considerable experimental and clinical
background leading to our decision to place decellularized
cryopreserved aortic homografts in the aortic position. In a
porcine superior vena cava replacement model, decellular-
ized cryopreserved vena cava homografts were completely
repopulated by the recipient with an endothelial lining.10
Stains for T-cell surface antigen, CD4, and CD8 yielded
negative results. Neoendothelial cells stained for factor
VIII. Smooth muscle cells in arteriole walls stained for
smooth muscle actin, and cells scattered in the adventitia
stained for procollagen type I. Elkins and coworkers14 re-
ported recellularization of both porcine and ovine decellu-
larized cryopreserved pulmonary valve conduits after im-
plantation into both the aortic and pulmonary positions in an
ovine model. After 11 months, leaflet explants had no
detectable inflammatory cells and were as much as 80%
repopulated with fibrocytes and smooth muscle cells stain-
ing for procollagen type I and smooth muscle actin, respec-
tively. The recellularization of the cusps appeared to
progress from the conduit wall, either from the adjacent
myocardium or from neovascularization of the implant.
Cusp free margin repopulation did not occur before the
midportion of the cusp was recellularized. A functional
recolonization process was also found in SynerGraft-treated
bovine ureters implanted as arteriovenous fistulas in a ca-
nine model.22 After 24 weeks, the matrixes were fully
colonized, with procollagen synthesis demonstrated. Im-
The Journal of Thoracicplant incorporation into the surrounding subcutaneous tissue
was noted. Elongated cells staining for smooth muscle actin
were noted. In all these experimental models, the decellu-
larized tissue maintained functional integrity. Grauss and
associates23 studied a similar detergent-enzymatic (ribonu-
clease and deoxyribonuclease) extraction method on rat
aortic valve conduits. Transplanted decellularized conduits
were completely acellular, with minimal damage to the
extracellular matrix. Functionally, the leaflets remained nor-
mal, unlike cellular allogeneic control grafts, which became
deformed, swollen, and acellular, with major changes in the
extracellular matrix. Oei and colleagues24 determined that
the cryopreservation process alone minimally affected the
extracellular matrix but left abundant HLA class II–positive
endothelial cells.
Clinically, the lack of antigenicity of decellularized tis-
sue has been encouraging. Decellularized cryopreserved
human femoral veins implanted for arteriovenous fistula to
be used for renal dialysis access resulted in no measurable
reactive antibody, as contrasted with the broad immunore-
activity incited by nondecellularized femoral veins.15 The
lack of immunoreactivity has also been shown in a large
series of patients receiving a decellularized cryopreserved
pulmonary homograft for pulmonary valve conduit replace-
ments in the Ross procedure.16 Eighty-eight percent of
patients (43/49) had no humoral immune response at 3
months. Bechtel and colleagues25 found no anti–class I
HLA antibodies in 24 patients receiving a decellularized
cryopreserved pulmonary valve conduit, in contrast to 66%
of 22 patients receiving a traditional cryopreserved pulmo-
nary homograft. In a pediatric population, Hawkins and
associates26 demonstrated significantly lower levels of class
I and class II HLA antibody formation at 1, 3, and 12
months than with standard cryopreserved allografts.
The lack of antigenicity of decellularized matrixes ap-
pears to vary when transplanted in a xenograft model. When
decellularized porcine conduits are placed in an ovine
model, 80% of the matrixes are repopulated with host fi-
broblasts.14,27 In contrast, Simon and coworkers28 have
reported on early failure of SynerGraft-treated porcine con-
duits implanted into children. Early explants had a severe
foreign-body reaction, with infiltration of neutrophils and
macrophages and lymphocytes at late explantation. There
was no cell repopulation of the porcine matrix. The fibro-
blasts appeared to be unable to penetrate the matrix and
instead became encapsulated. Goldstein and colleagues27
have reported on 3 patients (3 with aortic valve conduits and
2 with pulmonary valve conduits) with good early func-
tional results with decellularized porcine conduits. These
results suggest caution regarding application of decellular-
ized xenograft matrixes to the human situation, particularly
in children.
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cess to aortic valve conduits is their significant bulkiness
and thickness in relation to the other tissues. This could
have implications on the completeness and uniformity of
antigen removal. Of some concern, in an early experience
with decellularized cryopreserved aortic valve conduit ho-
mografts reported in part by Elkins,29 25% of 22 patients
had a humoral response. These were the first clinically
implanted SynerGraft-treated allografts. It is known that the
decellularization process can be variably complete, which
may have played a role in this early experience. In contrast,
the patients in our study have shown a remarkable lack of
immunoreactivity of the decellularized cryopreserved aortic
valve conduits with complete follow-up to 1 year.
Before this study, previous clinical applications were
directed toward small-caliber vessels (femoral vein), which
are subjected to systemic pressure but relatively low wall
tension because of the diameter of the vessel, and pulmo-
nary valve conduits, which are subjected to relatively low
pulmonary artery pressures. Biomechanical evaluations of
tensile strength, modulus extensibility, stress relaxation, and
static creep have been analyzed in SynerGraft allograft
aortic valves, pulmonary valves, femoral arteries, and fem-
oral veins and compared with those of standard cryopre-
served tissue. All parameters measured were within the
ranges usually observed for fibrillar connective tissue ma-
trixes. No differences were noted relative to standard cryo-
preserved tissue. Ultrastructural integrity of the SynerGraft
tissue matrix, as determined by thermal denaturation tem-
perature, has been found to be equivalent to that of standard
cryopreserved tissue. The aortic valve conduits used in this
study had a similar gross appearance to standard homografts
(Figure 3). The tissue handling attributes and the ability to
hold sutures were subjectively identical to those of standard
cryopreserved tissue. We observed no short-term durability
issues. The valve conduits held up in the setting of systemic
circulatory hemodynamics to a mean of 30 months. The
valve gradients were nearly identical to those at hospital
discharge, and no valves had more than trivial regurgitation.
Bechtel and colleagues25 showed similar hemodynamic re-
sults in a report of their initial experience with decellular-
ized cryopreserved pulmonary homografts in the pulmonary
position in 17 patients. At 6 months of follow-up, the
SynerGraft group had similar transhomograft pressure gra-
dients and minimal loss in measured orifice area, as opposed
to a significant rise in peak and mean gradients and loss of
orifice area in a matched control group of 17 patients
undergoing the Ross procedure with a standard cryopre-
served pulmonary homograft. The future may be one step
beyond decellularization. In the unique clinical experience
reported by Dohmen and colleagues,30 a decellularized pul-
monary homograft was seeded with viable autologous vas-
cular endothelial cells and implanted in the pulmonary
1014 The Journal of Thoracic and Cardiovascular Surgery ● Octposition in a patient undergoing a Ross procedure. Seeded
cellular viability was proved before implantation, and con-
duit hemodynamics were normal at 1-year follow-up, with
no evidence of calcification.
This report of our initial experience with implantation of
decellularized SynerGraft human aortic valve conduits in
the aortic position confirms their lack of immunoreactivity.
Early hemodynamic data appear equivalent to those of
standard homografts. Proof of cellular repopulation by do-
nor cells must await long-term follow-up showing lack of
calcification, improved durability, and evidence of donor
cells in tissue explants. If the conceptual ideas prove valid,
decellularized homografts may represent a significant ad-
vancement in homograft technology. The lack of allosensi-
tization clearly has ramifications for patients destined for
any future organ transplantation, and decellularized ho-
mografts should be considered as an alternative to standard
homografts in these patients.
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